Intedrated Imagaing and Tissue Biomarkers in Glioblastoma Multiforme Post Therapy

该项目的目标是确定数量特征的积分是否派生 ROM神经成像参数(磁共振波谱指数、脑血容量和 表观扩散系数)和组织生物标记物，并可预测患者的生物学行为 治疗后发生多形性胶质母细胞瘤(GBM)。标准磁共振成像(MRI)仅限于 评估治疗后普遍出现的增强增强的生物学行为。 尽管在大多数情况下，这是肿瘤进展的继发性疾病，但在以下局部治疗之后 对流增强的药物输送(CED)，增强可能是次要的治疗 效果。治疗后在新强化区域获得的病理标本通常由两者组成 “肿瘤”和“治疗效果”。目前还没有成熟的生物标记物来区分 肿瘤或治疗效果或可预测治疗后行为的放射学变化。在这 项目的目标将通过代谢和生理成像的评估来实现 区分治疗相关变化和肿瘤复发的参数。如果生理成像 可与肿瘤生物学或临床结局相关，这将允许重复使用安全、非 侵入性的，容易获得的生物标记物。这将对病人的护理和 神经肿瘤学临床试验的设计、实施和解释。有放射学定义的患者 进展“将在治疗复发之前进行研究，并跟踪临床结果以确定 如果特定的参数可以预测生物行为。这些信息将使我们深入了解成像 评价一种新化合物的CED效果所需的方法和预期的生理学 在CED的临床试验中，计划在治疗前后进行成像。这些研究将需要支持 临床服务核心和影像与组织相关核心

The objective of this project is to determine whether the integration of quantitative characteristics derived rom neuroimaging parameters (magnetic resonance spectroscopic indices, cerebral blood volume and apparent diffusion coefficient), with tissue biomarkers and are predictive of the biologic behavior for patients with glioblastoma multiforme (GBM) post therapy. Standard magnetic resonance imaging (MRI) is limited in assessing the biological behavior of increased enhancement which universally occurs post therapy. Although in the majority of cases this is secondary to tumor progression, following focal therapies such as convection enhanced delivery(CED) of agents, increased enhancement could be secondary to treatment effects. Pathologic specimens obtained post therapy in areas of new enhancement often consist of both 'tumor" and " treatment effect". There are currently no well-established biomarkers that distinguish between tumor or treatment effect or are predictive of the behavior of the radiographic changes post therapy. In this project the objectives will be accomplished by the evaluation of metabolic and physiologic imaging parameters to differentiate between treatment related changes and recurrent tumor. If physiologic imaging can be correlated with tumor biology or clinical outcome, this will allow for the repeated use of a safe, non- invasive, easily acquired biomarker. This will have significant implications to the care of patients and the design, conduct and interpretation of clinical trials in Neuro-Oncology. Patients with radiographically defined progression" will be studied prior to treatment for recurrence and followed for clinical outcome to determine if specific parameters are predictive of biological behavior. This information will give insight into the imaging methods required for evaluation of the effects of CED of a novel compound and prospective physiologic imaging is planned before and after treatment in a clinical trial of CED. These studies will require the support of the Clinical Services Core and the Imaging and Tissue Correlate Core